soluble TNF receptor 1 (sTNF RI) plasma
For the quantitative measurement of soluble Tumor Necrosis Factor receptor 1 (sTNFR1). The pro-inflammatory cytokine, TNFα and its soluble receptor, sTNFR1, are potent modulators of the inflammatory process.
The assay for quantification of sTNFR1 is a sandwich ELISA performed in a microtiter plate format. Conversion of a chromogenic substrate produces a color, the intensity of which is proportional to the concentration of sTNFR1 in the sample material. A standard curve is used to calculate the concentration of sTNFR1 in each of the test samples. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Specific to human sTNFR1.
3 business days from receipt of specimen
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
|plasma||30145||84238||Yes||1 mL||0.2 - 16 ng/mL||
The reference range varies for each allergen
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor Eurofins test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor Eurofins, 1001 NW Technology Dr, Lee's Summit, MO 64086.
Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
August KJ, Chiang KY, Bostick RM, et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transpl. 2011 46:601-604.
dePablo R, Monserrat J, Reyes E, et al. Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. J Intensive Care Med. 2011 26(2):125-132.
Sakata N, Yasui M, Okamura T, et al. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transpl. 2001 27:1153-1161.
Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. lnflamm Bowel Dis. 2007 13(6): 727-732.
Glossop JR, Dawes PT, Nixon NB, et al. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther. 2005 7(6):R1227-1234.
Majewski S, Wojas-Pelc A, Malejczyk M, et al. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999 9(3):207-210.
Choi SW, Stiff P, Cooke K, et al. TNF-Inhibition with Etanercept for Graft-versus-Host disease prevention in high risk HCT: Lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transpl. 2012 18:1517-1524.
Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute
graft-versus-host disease. Blood. 2009 113(2):273-278.
Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012 119(16):3854-3860.